Quality Choice Urinary Pain Relief Tablet
NDC 83324-201
Product Information
Quality Choice Urinary Pain Relief (phenazopyridine hydrochloride) is a UNAPPROVED DRUG OTHER-approved product labeled by Chain Drug Marketing Association. This product is primarily utilized in pharmaceutical processing or compounding. It is supplied as a red tablet for oral administration. This product entry covers the primary NDC 83324-201 and its associated package configuration. This profile includes active and inactive ingredient UNII references and FDA labeling data.
Primary Identification
Clinical Specifications
Labeler & Regulatory Data
Marketing Timeline
Product Characteristics
P95
Code Structure Chart
Product Details
What is NDC 83324-201?
What are the uses of this product?
What are Active Ingredients of this product?
- PHENAZOPYRIDINE HYDROCHLORIDE 95 mg/1 - A local anesthetic that has been used in urinary tract disorders. Its use is limited by problems with toxicity (primarily blood disorders) and potential carcinogenicity.
Which are the associated UNII Codes?
The UNII codes for the active ingredients in this product are:
- PHENAZOPYRIDINE HYDROCHLORIDE (UNII: 0EWG668W17)
- PHENAZOPYRIDINE (UNII: K2J09EMJ52) (Active Moiety)
Which are the Inactive Ingredients associated UNII Codes?
The inactive ingredients are all the component of a medicinal product OTHER than the active ingredient(s). The acronym "UNII" stands for “Unique Ingredient Identifier” and is used to identify each inactive ingredient present in a product. The UNII codes for the inactive ingredients in this product are:
- MAGNESIUM STEARATE (UNII: 70097M6I30)
- CELLULOSE, MICROCRYSTALLINE (UNII: OP1R32D61U)
- SHELLAC (UNII: 46N107B71O)
- CROSCARMELLOSE SODIUM (UNII: M28OL1HH48)
- SODIUM STARCH GLYCOLATE TYPE A CORN (UNII: AG9B65PV6B)
- LACTOSE (UNII: J2B2A4N98G)
- MAGNESIUM SILICATE (UNII: 9B9691B2N9)
What is the NDC to RxNorm Crosswalk for this product?
- RxCUI: 1094126 - phenazopyridine HCl 95 MG Oral Tablet
- RxCUI: 1094126 - phenazopyridine hydrochloride 95 MG Oral Tablet
* Please review the full disclaimer at the bottom of this page.